1589 related articles for article (PubMed ID: 7554977)
1. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
Xiao B; Zeng T; Wu S; Sun H; Xiao N
Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
[TBL] [Abstract][Full Text] [Related]
2. Ovarian function after seven years' use of a levonorgestrel IUD.
Barbosa I; Olsson SE; Odlind V; Goncalves T; Coutinho E
Adv Contracept; 1995 Jun; 11(2):85-95. PubMed ID: 7491859
[TBL] [Abstract][Full Text] [Related]
3. Ovarian function during use of a levonorgestrel-releasing IUD.
Barbosa I; Bakos O; Olsson SE; Odlind V; Johansson ED
Contraception; 1990 Jul; 42(1):51-66. PubMed ID: 2117516
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions.
Heikinheimo O; Gordon K; Williams RF; Hodgen GD
Contraception; 1996 Jan; 53(1):55-64. PubMed ID: 8631191
[TBL] [Abstract][Full Text] [Related]
5. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
[TBL] [Abstract][Full Text] [Related]
6. Ultrasonographic and endocrine evaluation of ovarian function among Norplant implants users with regular menses.
Alvarez F; Brache V; Faundes A; Tejada AS; Thevenin F
Contraception; 1996 Nov; 54(5):275-9. PubMed ID: 8934060
[TBL] [Abstract][Full Text] [Related]
7. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters.
Croxatto HB; Massai MR; Salvatierra AM; Fuentealba B; Croxatto HD; Lähteenmäki P
Contraception; 1996 Aug; 54(2):79-86. PubMed ID: 8842583
[TBL] [Abstract][Full Text] [Related]
8. Intracervical and fundal administration of levonorgestrel for contraception: endometrial thickness, patterns of bleeding, and persisting ovarian follicles.
Pakarinen PI; Suvisaari J; Luukkainen T; Lähteenmäki P
Fertil Steril; 1997 Jul; 68(1):59-64. PubMed ID: 9207585
[TBL] [Abstract][Full Text] [Related]
9. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.
Rossmanith WG; Steffens D; Schramm G
Contraception; 1997 Jul; 56(1):23-30. PubMed ID: 9306028
[TBL] [Abstract][Full Text] [Related]
10. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.
Luukkainen T; Toivonen J
Contraception; 1995 Nov; 52(5):269-76. PubMed ID: 8585882
[TBL] [Abstract][Full Text] [Related]
11. Effects of a single contraceptive Silastic implant containing nomegestrol acetate on ovarian function and cervical mucus production during 2 years.
Barbosa I; Coutinho E; Hirsch C; Ladipo O; Olsson SE; Ulmsten U
Fertil Steril; 1996 Apr; 65(4):724-9. PubMed ID: 8654629
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device.
Xiao BL; Zhou LY; Zhang XL; Jia MC; Luukkainen T; Allonen H
Contraception; 1990 Apr; 41(4):353-62. PubMed ID: 2335100
[TBL] [Abstract][Full Text] [Related]
13. A morphometric study on the endometrial activity of women before and after one year with LNG-IUD in situ.
Gu Z; Zhu P; Luo H; Zhu X; Zhang G; Wu S
Contraception; 1995 Jul; 52(1):57-61. PubMed ID: 8521716
[TBL] [Abstract][Full Text] [Related]
14. Hormonal intrauterine devices.
Rybo G; Andersson K; Odlind V
Ann Med; 1993 Apr; 25(2):143-7. PubMed ID: 8489751
[TBL] [Abstract][Full Text] [Related]
15. Lipid effects of an intrauterine levonorgestrel device or oral vs. vaginal natural progesterone in post-menopausal women treated with percutaneous estradiol.
Suvanto-Luukkonen E; Sundström H; Penttinen J; Kauppila A
Arch Gynecol Obstet; 1998; 261(4):201-8. PubMed ID: 9789651
[TBL] [Abstract][Full Text] [Related]
16. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system.
Suvisaari J; Lähteenmäki P
Contraception; 1996 Oct; 54(4):201-8. PubMed ID: 8922872
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
[TBL] [Abstract][Full Text] [Related]
18. Morphometric study of the human endometrium following continuous exposure to levonorgestrel released from vaginal rings during 90 days.
Johannisson E; Brosens I; Cornillie F; Elder M; White J; Sheppard B; Hourihan H; d'Arcangues C; Belsey EM
Contraception; 1991 Apr; 43(4):361-74. PubMed ID: 1906792
[TBL] [Abstract][Full Text] [Related]
19. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
[TBL] [Abstract][Full Text] [Related]
20. Plasma levonorgestrel levels and ovarian function during the use of a levonorgestrel-releasing intracervical contraceptive device.
Ratsula K; Toivonen J; Lähteenmäki P; Luukkainen T
Contraception; 1989 Feb; 39(2):195-204. PubMed ID: 2495893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]